The effect of norepinephrine on insulin secretion and glucose effectiveness in non-insulin-dependent diabetes

Metabolism: Clinical and Experimental
J M WaltersF Alford

Abstract

It has previously been shown that in normal subjects, physiological elevation of norepinephrine (NE) impairs insulin sensitivity (Si) but does not influence insulin secretion. The aim of this study was to determine the effect of short-term physiological elevation of NE on insulin secretion, Si, and glucose-mediated glucose disposal, or the glucose effectiveness index (Sg), in non-insulin-dependent diabetes mellitus (NIDDM). Two intravenous glucose tolerance tests (IVGTTs) were performed in eight well-controlled NIDDM patients, using a supplemental exogenous insulin infusion to achieve an approximation of normal endogenous insulin secretion. The IVGTTs were performed in random order after 30 minutes of either the saline (SAL) or NE (25 ng/kg/min) infusions, which were continued throughout the 3-hour IVGTT. Sg and Si were estimated by minimal model analysis of the IVGTT data as previously described. Plasma C-peptide was used to estimate insulin secretion rate using the ISEC program. NE infusion produced approximately a threefold increase in plasma NE, associated with (1) a significant reduction in glucose disposal ([KG] SAL v NE, 0.73 +/- 0.06 v 0.61 +/- 0.06 x 10(-2).min-1, P < .05), (2) no reduction in Si (2.33 +/- 0.8 v 2.62 +...Continue Reading

References

Oct 1, 1990·The Journal of Clinical Endocrinology and Metabolism·S E KahnD Porte
Jan 1, 1988·Diabetic Medicine : a Journal of the British Diabetic Association·P A CrockJ D Best
Sep 1, 1988·Metabolism: Clinical and Experimental·A G MarangouJ D Best
Apr 1, 1980·The Journal of Clinical Endocrinology and Metabolism·L SaccàB Ungaro
Mar 1, 1981·Computer Programs in Biomedicine·R C BostonM Berman
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Sep 14, 1996·BMJ : British Medical Journal·G Davey, P Mckeigue

❮ Previous
Next ❯

Citations

Nov 13, 2003·International Journal of Immunopathology and Pharmacology·R RamakrishnanA Namasivayam
Apr 25, 2009·Diabetic Medicine : a Journal of the British Diabetic Association·P LeeL V Campbell
Jul 13, 2019·Pharmacoepidemiology and Drug Safety·Paige D WartkoSascha Dublin
Apr 30, 2019·Journal of Cellular Physiology·Yanan KongYu Zhao
Jun 15, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Bayan MesmarRana Malek
Jun 9, 2018·SAGE Open Medicine·Alex AregbesolaJussi Kauhanen
Mar 16, 2001·Expert Opinion on Pharmacotherapy·P J Goodnick, M Hernandez
Feb 16, 2005·Expert Opinion on Drug Safety·Jambur Ananth, Smita Kolli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.